Cost-Effectiveness of Interferon Alfa-2b Added to Chemotherapy for High-Tumor-Burden Follicular Non-Hodgkin's Lymphoma

References

• Portlock C S. Management of the low-grade non-Hodgkin's lymphomas. Seminars in Oncology 1990; 17: 51–59
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Vose J M. Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy. Annals of Oncology 1996; 7((Suppl 6))S13–S19
   PubMed Web of Science ®Google Scholar
• Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Seminars in Oncology 1993; 20(Suppl 5)75–88
   PubMed Web of Science ®Google Scholar
• Kalter S, Holmes L, Cabanillas F. Long-term results of treatment of patients with follicular lymphomas. Hematological Oncology 1987; 5: 127–138
   PubMed Web of Science ®Google Scholar
• Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Diamond H D, Jaslowitz B, Craver L F. Lymphosarcoma: a review of 1269 cases. Medicine 1961; 40: 31–84
   PubMed Web of Science ®Google Scholar
• Jones S E, Fuks Z, Bull M, Kadin M E, Dorfman R F, Kaplan H S, Rosenberg S A, Kim H. Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer 1973; 31: 806–823
   Google Scholar
• Rudders R A, Kaddis M, DeLellis R A, Casey H, Jr. Nodular non-Hodgkin's lymphoma (NHL): factors influencing prognosis and indications for aggressive treatment. Cancer 1979; 43: 1643–1651
   PubMed Web of Science ®Google Scholar
• Stein R S, Cousar J, Flexner J M, Graber S E, McKee L C, Krantz S, Collins R D. Malignant lymphomas of follicular center cell origin in man. III. Prognostic features. Cancer 1979; 44: 2236–2243
   Google Scholar
• Anderson T, DeVita VT, Jr, Simon R M, Berard C W, Canellos G P, Garvin A J, Young R. C. Malignant lymphoma. II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708–2721
   Google Scholar
• Litam P, Swan F, Cabanillas F, Tucker S L, McLaughlin P, Hagemeister F B, Rodriguez MS, Velasquez W S. Prognostic value of serum β-2 microglobulin in low-grade lymphoma. Annals of Internal Medicine 1991; 114: 855–860
   PubMed Web of Science ®Google Scholar
• Martin A R, Weisenburger D D, Chan W C, Ruby E I, Anderson J R, Vose J M, Bierman P J, Bast M A, Daley D T, Armitage J O. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85: 3671–3678
   PubMed Web of Science ®Google Scholar
• Gallagher C J, Gregory W M, Jones A E, Stansfeld A G, Richards M A, Dhaliwal H S, Malpas J S, Lister T A. Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Bastion Y, Berger F, Bryon P A, Felman P, Ffrench M, Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Annals of Oncology 1991; 2((Suppl 2))123–129
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Eghbali H, Bonichon F, Trojani M, Richaud P, Hoerni B. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. European Journal of Cancer 1991; 27: 1606–1613
   PubMed Web of Science ®Google Scholar
• Romaguera J E, McLaughlin P, North L, Dixon D, Silvermintz K B, Gamsey L A, Velasquez W S, Hagemeister F B, Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. Journal of Clinical Oncology 1991; 9: 762–769
   PubMed Web of Science ®Google Scholar
• Cameron D A, Leonard R C, Mao J H, Prescott R J. Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Leukemia and Lymphoma 1993; 10: 89–99
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Montserrat E, Bosch F, Terol M J, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. Journal of Clinical Oncology 1994; 12: 1343–1348
   PubMed Web of Science ®Google Scholar
• Hermans J, Krol A DG, van Groningen K, Kluin PhM, Kluin-Nelemans J C, Kramer M HH, Noordijk E M, Ong F, Wijermans P W. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood, 86: 1460–1463
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lapage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, Coiffier B, Gisselbrecht C. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. New England Journal of Medicine 1993; 329: 1608–1614, for the Groupe d'Etude des Lymphomes de l'Adulte.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, Tendler C L, Brice P, Haioun C, Gabarre J, Pignon B, Tertian G, Bouabdallah R, Rossi J F, Doyen C, Coiffier B. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. Journal of Clinical Oncology 1998; 16: 2332–2338
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lapage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 1997; 15: 1110–1117
   PubMed Web of Science ®Google Scholar
• Sonnenberg F A, Beck J R. Markov models in medical decision making: a practical guide. Medical Decision Making 1993; 13: 322–338
   PubMed Web of Science ®Google Scholar
• Beck J R, Kassirer J P, Pauker S G. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. American Journal of Medicine 1982; 73: 883–888
   PubMed Web of Science ®Google Scholar
• Wong J B, Koff R S, Tine F, Pauker S G. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Annals of Internal Medicine 1995; 122: 664–675
   PubMed Web of Science ®Google Scholar
• Gelber R D, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. Journal of Clinical Oncology 1986; 4: 1772–1779
   PubMed Web of Science ®Google Scholar
• Gelber R D, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Annals of Internal Medicine 1991; 114: 621–628, for the International Breast Cancer Study Group.
   PubMed Web of Science ®Google Scholar
• Gelber R D, Goldhirsch A, Hurny C, Bernhard J, Simes R J. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). Journal of the National Cancer Institute Monographs 1992; 11: 127–135
   PubMedGoogle Scholar
• Gelber R D, Cole B F, Goldhirsch A, Rose C, Fisher B, Osborne C K, Boccardo F, Gray R, Gordon N H, Bengtsson N O, Sevelda P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347(9008)1066–1071
   PubMed Web of Science ®Google Scholar
• Cole B F, Solal-Celigny P, Gelber R D, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. Journal of Clinical Oncology 1998; 16: 2339–2344
   PubMed Web of Science ®Google Scholar
• Kattan M W, Inoue Y, Giles F J, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber S L, Beck J R. Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. Annals of Internal Medicine 1996; 125: 541–548
   PubMed Web of Science ®Google Scholar
• Messori A, Becagli P, Trippoli S. Cost-effectiveness of interferon-alpha as maintenance therapy in chronic myelogenous leukemia. Annals of Internal Medicine 1997; 126: 664–665
   PubMed Web of Science ®Google Scholar
• Price C G, Rohatiner A Z, Steward W, Deakin D, Bailey N, Norton A, Blackledge G, Crowther D, Lister T A. Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Annals of Oncology 1991; 2(Suppl 2)141–145
   PubMed Web of Science ®Google Scholar
• Smalley R V, Andersen J W, Hawkins M J, Bhide V, O'Connell M J, Oken M M, Borden E C. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. New England Journal of Medicine 1992; 327: 1336–1341
   PubMed Web of Science ®Google Scholar
• Andersen J W, Smalley R V. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up [Letter]. New England Journal of Medicine 1993; 329: 1821–1822
   PubMed Web of Science ®Google Scholar
• Peterson B A, Petroni G, Oken M M, Ozer H. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486) [Abstract #1240]. CALGB and ECOG, Lebanon, NH and Denver, CO. Proceedings of the American Society of Clinical Oncology 1993; 12: 366
   Google Scholar
• Rohatiner A, Lister T A. Management of follicular lymphoma. Current Opinion in Oncology 1994; 6: 473–479
   PubMedGoogle Scholar
• Smalley R, Weller E, Hawkins M, Oken M, O'Connell M, Haase-Statz S, Borden E. α Interferon in non-Hodgkins lymphoma — an update of the ECOG I-COPA trial (E6484) [Abstract #2004]. Blood 1998; 92((Suppl 1))486a
   Google Scholar
• Rohatiner A ZS, Gregory W, Peterson B, (CALGB + ECOG), Smalley R, (ECOG), Solal-Celigny P, (GELF), Hagenbeek A, (EORTC), Bijnens L, (EORTC), Unterhalt M, (GLSG), Chisesi T, Aviles A, Lister T A. A meta-analysis (MA) of randomised trials evaluating the role of interferon (IFN) as treatment for follicular lymphoma (FL) [Abstract #11]. Proceedings of the American Society of Clinical Oncology 1998; 17: 4a
   Google Scholar
• Smith T J, Hillner B E, Desch C E. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. Journal of the National Cancer Institute 1993; 85: 1460–1474
   PubMed Web of Science ®Google Scholar
• Weeks J C, Tierney M R, Weinstein M C. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. New England Journal of Medicine 1991; 325: 81–86
   PubMed Web of Science ®Google Scholar
• Hillner B E, Smith T J, Desch C E. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 1992; 267: 2055–2061
   PubMed Web of Science ®Google Scholar
• Smith T J, Hillner B E. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. Journal of Clinical Oncology 1993; 11: 771–776
   PubMed Web of Science ®Google Scholar
• Bennett W G, Inoue Y, Beck J R, Wong J B, Pauker S G, Davis G L. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine 1997; 127: 855–865
   PubMed Web of Science ®Google Scholar
• Wagner J L, Herdman R C, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Annals of Internal Medicine 1991; 115: 807–817
   PubMed Web of Science ®Google Scholar
• Sisk J E, Riegelman R K. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Annals of Internal Medicine 1986; 104: 79–86
   PubMed Web of Science ®Google Scholar
• Wong J B, Sonnenberg F A, Salem D N, Pauker S. G. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Annals of Internal Medicine 1990; 113: 852–871
   PubMed Web of Science ®Google Scholar